Global Helicobacter Pylori Diagnostics Market Growth (Status and Outlook) 2023-2029

Global Helicobacter Pylori Diagnostics Market Growth (Status and Outlook) 2023-2029

Helicobacter pylori (H. pylori) is a Gram-negative, microaerobic human pathogen and H. pylori infection is strongly related with many gastroduodenal diseases including chronic active gastritis, peptic ulcer diseases, atrophic gastritis, mucosa associated lymphoid tissue (MALT) lymphoma and noncardia gastric cancer. H. pylori infection affects more than half of the adult population worldwide, but the prevalence of H pylori infection varies widely by geographic area, age, race, and socioeconomic status. Usually, the prevalence of H. pylori increases with age in most countries, however a decline in prevalence of H. pylori infection has been observed in recent decades in time trend analysis of several large populations. More than 80% of peptic ulcer diseases are caused by H. pylori infection and the estimated lifetime risk for peptic ulcer disease in H. pylori-infected patients is approximately 15%. Gastric cancer is the third leading cause of cancer-related death worldwide and H. pylori infection is responsible for 74.7% of all noncardia gastric cancer cases. Gastric cancer and peptic ulcer together cause more than a million deaths per year in the world and H. pylori infection always is an important health issue. Various diagnostic methods are developed to detect H. pylori infection and diagnostic tests with both high sensitivity and specificity, exceeding 90%, are necessary for accurate diagnosis of H. pylori infection in clinical practice. Although many diagnostic tests are available now, each method has its own advantages, disadvantages, and limitations. The choice of one method or another could be depended on availability and accessibility of diagnostic tests, level of laboratories, clinical conditions of patients, and likelihood ratio of positive and negative tests on different clinical circumstances. Diagnostic tests are usually divided into invasive (endoscopic-based) and noninvasive methods. Invasive diagnostic tests include endoscopic image, histology, rapid urease test, culture, and molecular methods. Non-invasive diagnostic tests included Non-invasive Techniques, stool antigen test, serological, and molecular examinations. In the present report, we mainly studies the Helicobacter pylori diagnostic reagent or test box market status and outlook of global and major regions, from angles of players, regions, product and end Application/industries; this report analyzes the top players in global and major regions, and splits the Helicobacter Pylori Diagnostics market by product and Application/end industries.
LPI (LP Information)' newest research report, the “Helicobacter Pylori Diagnostics Industry Forecast” looks at past sales and reviews total world Helicobacter Pylori Diagnostics sales in 2022, providing a comprehensive analysis by region and market sector of projected Helicobacter Pylori Diagnostics sales for 2023 through 2029. With Helicobacter Pylori Diagnostics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Helicobacter Pylori Diagnostics industry.
This Insight Report provides a comprehensive analysis of the global Helicobacter Pylori Diagnostics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Helicobacter Pylori Diagnostics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Helicobacter Pylori Diagnostics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Helicobacter Pylori Diagnostics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Helicobacter Pylori Diagnostics.
The global Helicobacter Pylori Diagnostics market size is projected to grow from US$ 624.1 million in 2022 to US$ 1040.4 million in 2029; it is expected to grow at a CAGR of 7.6% from 2023 to 2029.
Global Helicobacter Pylori Diagnostics key players include Sekisui Diagnostics, Medline Industries, F. Hoffmann-La Roche, Meridian Bioscience, Bio-Rad Laboratories, etc. Global top five manufacturers hold a share about 85%. Europe is the largest market, with a share about 30%, followed by Asia-Pacific and North America, both with a share about 25 percent. In terms of product, Non-invasive Techniques is the largest segment, with a share about 80%. And in terms of application, the largest application is Hospitals and Clinics, followed by Diagnostic Laboratories, etc.
This report presents a comprehensive overview, market shares, and growth opportunities of Helicobacter Pylori Diagnostics market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Invasive Techniques
Non-invasive Techniques
Segmentation by application
Hospitals and Clinics
Diagnostic Laboratories
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Sekisui Diagnostics
F. Hoffmann-La Roche
Medline Industries
Meridian Bioscience
Bio-Rad Laboratories
Thermo Fisher Scientific
Alpha Laboratories
EKF Diagnostics
Quidel
Halyard Health
Cardinal Health
Beckman Coulter
Agilent Technologies
Coris BioConcept

Please note: The report will take approximately 2 business days to prepare and deliver.